Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Nkarta, Inc.
Verismo Therapeutics
Stanford University
Poseida Therapeutics, Inc.
LTZ Therapeutics, Inc.
University Health Network, Toronto
University of Arizona
Mayo Clinic
Chengdu Zenitar Biomedical Technology Co., Ltd
University of Nebraska
Florida International University
Shanghai Exuma Biotechnology Ltd.